NCT00881816UnknownPhase 1
Phase I Clinical Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma
Nanjing Sike Pharmaceutical Co., Ltd.0 sites15 target enrollmentStarted: April 2009Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Enrollment
- 15
- Primary Endpoint
- maximum tolerated dose
Study Overview
Brief Summary
The purpose of this study is to determine the maximum tolerated dose and dose limiting toxicity of liposomal paclitaxel plus capecitabine in Chinese patients with advanced gastric carcinoma.
Detailed Description
There are clinical trials showed that taxane is optional for the treatment of gastric cancer. Liposomal paclitaxel has different pharmacokinetic features comparing with conventional taxane. This study is designed to find the maximum tolerated dose and dose limiting toxicity of liposomal paclitaxel combined with capecitabine in Chinese patients with advanced gastric carcinoma.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age: 18 to 75
- •Histologically or cytologically documented gastric adenocarcinoma and esophagus-gastro adenocarcinoma of metastatic or advanced stages with/without measurable tumor according to RECIST standard
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
- •Patients who are expected to live at least 3 months
- •No prior systemic chemotherapy with advanced stereo- tumor before the recruitment(recidivist/ metastatic without perioperative chemotherapy at least 6m)
- •No Previous anaphylactic reaction to hormone
- •Obtaining informed consent
- •Patients may comply with the study protocol
- •Laboratory tests: Absolute neutrophil count (ANC) ≥2,000/mm³, Platelet count ≥100,000/mm³, Hemoglobin ≥9.0 g/dL, Serum creatinine≤1.5 x the institutional upper limit of normal (ULN), Creatinine clearance≥50ml/min，Total bilirubin≤1.5 x the institutional upper limit of normal (ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5 x ULN. In the case of known liver metastasis, ALT and AST（SGOT） ≤1.5 x ULN.
Exclusion Criteria
- •Active uncontrolled central nervous system metastasis
- •No adequate organ function or known disease :
- •myocardial infarction
- •active heart disease
- •neuropathy or mental diseases including dementia or epilepsy
- •blind、deaf、dumb or extremity disability
- •known infection
- •active diffuse intravascular coagulation
- •known infection with hepatitis virus
- •Pregnant or nursing,fertile patients would not use effective contraception during study treatment
- •Prior clinically significant gastrointestinal tract disease , that would influence obviously capecitabine to absorb,including the ability to swallow by the attending physician
- •No other active malignancies except that in complete remission with squamous cell carcinoma in situ of the cervix or anus, completely resected basal cell carcinoma, or no recrudescence for at least 2 year from the time a response was first documented
- •Having other study medication within 4w
- •Having radiation therapy or operation within 4w
- •Any non-remission toxicity ≥ CTC 1 in prior anticancer therapy(including radiation therapy) (except alopecie and hemoglobin)
- •Peripheral nerve disease ≥ 2
- •Previous anaphylactic reaction to Capecitabine and Paclitaxel or diluents bases
- •Absence of dihydropyrimidine dehydrogenase
- •Patients not suitable determined by the attending physician.
Arms & Interventions
Liposomal paclitaxel plus capecitabine
Experimental
Intervention: Liposomal paclitaxel plus capecitabine (Drug)
Outcomes
Primary Outcomes
maximum tolerated dose
Time Frame: 6 months
Secondary Outcomes
- dose limiting toxicity(6 months)
Investigators
Similar Trials
Unknown
Phase 1
Clinical Study of Liposomal Paclitaxel in Chinese PatientsSolid TumorNCT00881101Nanjing Sike Pharmaceutical Co., Ltd.15
Completed
Phase 1
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced CancerNeoplasmNCT00080418INSYS Therapeutics Inc40
Completed
Phase 1
Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory MalignancyNeoplasmsNCT00001387National Cancer Institute (NCI)25
Unknown
Phase 1
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric CarcinomaGastric CarcinomaNCT00639522Nanjing Sike Pharmaceutical Co., Ltd.18
Unknown
Phase 4
Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional TreatmentsSolid TumorsNCT01994031Nanjing Luye Sike Pharmaceutical Co., Ltd.36